

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

LX-2

RRID:CVCL_5792

Type: Cell Line

Proper Citation

Millipore Cat# SCC064, RRID:CVCL_5792

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5792

Proper Citation: Millipore Cat# SCC064, RRID:CVCL_5792

Description: Cell line LX-2 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:15591520](#), [PMID:17760834](#), [PMID:19085953](#), [PMID:21930125](#), [PMID:22694338](#), [PMID:24116068](#), [PMID:34884585](#)

Comments: Anecdotal: Cell line name is derived from the name of the first author of the original paper., Characteristics: Able to grow under reduced serum conditions (1% FBS) (PubMed=15591520).

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: LX-2

Synonyms: Lieming Xu-2

Cross References: BTO:BTO_0003516, EFO:EFO_0022711, ChEMBL-Cells:ChEMBL4879539, CLS:305039, Hysigen:TCH-C391, Lonza:616, Millipore:SCC064, PRIDE:PRD000680, PRIDE:PXD029121, SKY/M-FISH/CGH:5853, Wikidata:Q54903298

ID: CVCL_5792

Vendor: Millipore

Catalog Number: SCC064

Hierarchy: cvcl_5790

Record Creation Time: 20220427T220738+0000

Record Last Update: 20260829T234533+0000

Ratings and Alerts

No rating or validation information has been found for LX-2.

No alerts have been found for LX-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 645 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yang JQ, et al. (2026) Asarinin alleviates hepatic fibrosis through TR β -STAT3 pathway: A new strategy by regulating liver microenvironment. Journal of ethnopharmacology, 368, 121759.

Liu L, et al. (2026) Curcumin Targets Crisp1d2 to Suppress Hepatic Stellate Cell Activation via PI3K/AKT Pathway Inhibition in Hepatic Fibrosis. Liver international : official journal of the International Association for the Study of the Liver, 46(6), e70696.

Guo X, et al. (2026) Curcumol Induces Necroptosis of Hepatic Stellate Cells by Targeting KAT8 to Suppress HK2 Lactylation and Promote HUWE1-Dependent Ubiquitination. International journal of biological sciences, 22(3), 1648.

Shang Y, et al. (2026) Inhibitory effect of Anwulignan on the IL-36R/TLR9 signaling pathway: potential therapeutic role in hepatic fibrosis. Phytomedicine : international journal of phytotherapy and phytopharmacology, 153, 157931.

Xu SY, et al. (2026) UPLC-MS/MS-Network Pharmacology and Experimental Validation Reveal Active Components of Ficus tikoua for Ameliorating Liver Fibrosis. Chemistry & biodiversity, 23(4), e71191.

Novoa E, et al. (2026) Lack of PCK1 in hepatic stellate cells causes liver fibrosis by fueling tricarboxylic acid cycle and increasing glycolysis. Cell metabolism, 38(4), 729.

Yu S, et al. (2026) Hepatic Stellate Cell-Specific METTL3 Deficiency Promotes Hepatocellular Carcinoma Progression via BMP10-SMAD1/5/8 Signaling. Cancer research communications, 6(5), 1109.

Álvarez-Guaita A, et al. (2026) Sex Hormone-Binding Globulin Prevents Carbon Tetrachloride-Induced Liver Fibrosis Development. *International journal of molecular sciences*, 27(11).

Weiskirchen R, et al. (2026) Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review. *Medical sciences (Basel, Switzerland)*, 14(1).

Mandala A, et al. (2026) Reprogramming offspring liver health: maternal indole supplementation as a preventive strategy against MASLD. *EBioMedicine*, 123, 106098.

Byun S, et al. (2026) Deubiquitinase USP2 promotes hepatic stellate cell activation via p300 stabilization. *FEBS letters*, 600(9), 1318.

Sun S, et al. (2026) Ammonia Detoxification Inhibits Liver Metastasis by Reshaping Hepatic Microenvironment. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(33), e21098.

Eid AM, et al. (2026) Potent Anticancer, Antimicrobial, and Anti-Inflammatory Activities of *Boswellia sacra* Extracted Oil Nanoemulgel. *BioMed research international*, 2026(1), e7034598.

Jin JY, et al. (2026) Deficient chaperone-mediated autophagy drives multiorgan fibrogenesis via SMAD2/4 stabilization to sustain TGF β -SMAD signaling. *Acta pharmacologica Sinica*.

Luan Q, et al. (2026) Ligustilide alleviates hepatic fibrosis by targeting the mesenchymal homeobox 1 (MEOX1)- transcriptional enhanced associate domain factor 2 (TEAD2) signalling axis. *British journal of pharmacology*, 183(16), 4818.

Sriramareddy S, et al. (2026) GDF15 Reprograms the Microenvironment to Drive Liver Metastasis of Uveal Melanoma. *Cancer research*.

Fu D, et al. (2026) ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(26), e16557.

Zhao Q, et al. (2026) Global molecular landscape of early MASLD progression in human obesity. *eLife*, 14.

Song X, et al. (2026) AI-driven network pharmacology and multi-omics validation identify KCNH2 as a prognostic biomarker and candidate therapeutic vulnerability of *Acorus tatarinowii* in glioblastoma. *Frontiers in pharmacology*, 17, 1811032.

Wang WL, et al. (2026) Rosavin mitigates hepatic fibrosis via KLF14-mediated suppression of P2X7 receptor-dependent inflammatory signaling cascades. *Journal of ethnopharmacology*, 370, 121949.